BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, Garrett JT. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel) 2020;12:E482. [PMID: 32092958 DOI: 10.3390/cancers12020482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Dreier MR, de la Serna IL. SWI/SNF Chromatin Remodeling Enzymes in Melanoma. Epigenomes 2022;6:10. [DOI: 10.3390/epigenomes6010010] [Reference Citation Analysis]
2 Zhao K, Dai Q, Wu J, Wei Z, Duan Y, Chen B. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. Eur J Cancer 2022;165:58-70. [PMID: 35219024 DOI: 10.1016/j.ejca.2022.01.004] [Reference Citation Analysis]
3 Homayun-Sepehr N, McCarter AL, Helaers R, Galant C, Boon LM, Brouillard P, Vikkula M, Dellinger MT. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib. JCI Insight 2021;6:149831. [PMID: 34156985 DOI: 10.1172/jci.insight.149831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jung T, Haist M, Kuske M, Grabbe S, Bros M. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Int J Mol Sci 2021;22:9890. [PMID: 34576054 DOI: 10.3390/ijms22189890] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'toole S, Saw RP, Amanuel B, Angel CM, Button-sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, Mcarthur GA, Mclean CA, Menzies AM, Nieweg OE, O'brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AH, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology 2021. [DOI: 10.1016/j.pathol.2021.11.002] [Reference Citation Analysis]
6 Khojasteh Poor F, Keivan M, Ramazii M, Ghaedrahmati F, Anbiyaiee A, Panahandeh S, Khoshnam SE, Farzaneh M. Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Dis 2021;40:51-62. [PMID: 33896802 DOI: 10.3233/BD-201063] [Reference Citation Analysis]
7 Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers (Basel) 2020;12:E1823. [PMID: 32645969 DOI: 10.3390/cancers12071823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
8 Bafaloukos D, Petraki K, Bousmpoukea A, Chatzichristou E, Pieris I, Koutserimpas C, Samonis G. Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases. Vaccines 2022;10:525. [DOI: 10.3390/vaccines10040525] [Reference Citation Analysis]
9 Yu L, Peng F, Dong X, Chen Y, Sun D, Jiang S, Deng C. Sex-Determining Region Y Chromosome-Related High-Mobility-Group Box 10 in Cancer: A Potential Therapeutic Target. Front Cell Dev Biol 2020;8:564740. [PMID: 33344444 DOI: 10.3389/fcell.2020.564740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C, Cheng F, Li J, Fang Q. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res 2021;163:105207. [PMID: 32971268 DOI: 10.1016/j.phrs.2020.105207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
11 Ghilu S, Kurmasheva RT, Houghton PJ. Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. J Clin Med 2021;10:1504. [PMID: 33916592 DOI: 10.3390/jcm10071504] [Reference Citation Analysis]
12 Booth L, West C, Von Hoff D, Kirkwood JM, Dent P. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Front Oncol 2021;11:656453. [PMID: 33898322 DOI: 10.3389/fonc.2021.656453] [Reference Citation Analysis]
13 Dent P, Booth L, Poklepovic A, Kirkwood JM. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res 2021. [PMID: 34482636 DOI: 10.1111/pcmr.13014] [Reference Citation Analysis]
14 Ren C, Ruan Y. Expression and clinical significance of five major genes in cutaneous melanoma based on TCGA database. Human Pathology: Case Reports 2020;21:200411. [DOI: 10.1016/j.ehpc.2020.200411] [Reference Citation Analysis]
15 Li H, Guo L, Cai Z. TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-022-02556-8] [Reference Citation Analysis]
16 Wu B, Zhang Z, Dou G, Lv X, Ge J, Wang H, Xie H, Zhu D. Novel natural inhibitors targeting B-RAF(V600E) by computational study. Bioengineered 2021;12:2970-83. [PMID: 34252351 DOI: 10.1080/21655979.2021.1943113] [Reference Citation Analysis]
17 Uranowska K, Samadaei M, Kalic T, Pinter M, Breiteneder H, Hafner C. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. Int J Oncol 2021;59:70. [PMID: 34318902 DOI: 10.3892/ijo.2021.5250] [Reference Citation Analysis]
18 Yang G, Liu S, Maghsoudloo M, Shasaltaneh MD, Kaboli PJ, Zhang C, Deng Y, Heidari H, Entezari M, Fu S, Wen Q, Imani S. PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer. Sci Rep 2021;11:6056. [PMID: 33723350 DOI: 10.1038/s41598-021-85595-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman VS, Hill RA, Kousoulas KG, Nagalo BM, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem 2021;107:104595. [PMID: 33450548 DOI: 10.1016/j.bioorg.2020.104595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Patel V, Szász I, Koroknai V, Kiss T, Balázs M. Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines. Cancers (Basel) 2021;13:6058. [PMID: 34885166 DOI: 10.3390/cancers13236058] [Reference Citation Analysis]
21 Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted Therapy in Melanoma and Mechanisms of Resistance. Int J Mol Sci 2020;21:E4576. [PMID: 32605090 DOI: 10.3390/ijms21134576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
22 Rahmati M, Ebrahim S, Hashemi S, Motamedi M, Moosavi MA. New insights on the role of autophagy in the pathogenesis and treatment of melanoma. Mol Biol Rep 2020;47:9021-32. [DOI: 10.1007/s11033-020-05886-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yuan L, Mishra R, Patel H, Alanazi S, Wei X, Ma Z, Garrett JT. BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels. Cancers (Basel) 2020;12:E1661. [PMID: 32585852 DOI: 10.3390/cancers12061661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Arteaga Ceballos DP, Saeed-Kamil Z, King I, Stockley T, Liu D, Muniz TP, Saibil SD, Hogg D, Spreafico A, Butler MO. Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center. JCO Oncol Pract 2022;:OP2100810. [PMID: 35363503 DOI: 10.1200/OP.21.00810] [Reference Citation Analysis]
25 Li N, Xu Y, Fan Y. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:714-22. [PMID: 34696543 DOI: 10.3779/j.issn.1009-3419.2021.101.29] [Reference Citation Analysis]
26 Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes (Basel) 2020;11:E1342. [PMID: 33198372 DOI: 10.3390/genes11111342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Apraiz A, Benedicto A, Marquez J, Agüera-Lorente A, Asumendi A, Olaso E, Arteta B. Innate Lymphoid Cells in the Malignant Melanoma Microenvironment. Cancers (Basel) 2020;12:E3177. [PMID: 33138017 DOI: 10.3390/cancers12113177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Fang X, Liu X, Weng C, Wu Y, Li B, Mao H, Guan M, Lu L, Liu G. Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma. Int J Med Sci 2020;17:2718-27. [PMID: 33162799 DOI: 10.7150/ijms.47224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wozniak M, Czyz M. The Functional Role of Long Non-Coding RNAs in Melanoma. Cancers (Basel) 2021;13:4848. [PMID: 34638331 DOI: 10.3390/cancers13194848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes (Basel) 2021;12:899. [PMID: 34200676 DOI: 10.3390/genes12060899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Fromme JE, Zigrino P. Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor. Br J Dermatol 2021. [PMID: 34590708 DOI: 10.1111/bjd.20756] [Reference Citation Analysis]
32 Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem GE, Saussez S, Colet JM, Journe F. Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers (Basel) 2020;12:E1323. [PMID: 32455924 DOI: 10.3390/cancers12051323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Li J, Long J, Zhang J, Liu N, Yan B, Tang L, Chen X, Peng C. Novel chloroquine derivative suppresses melanoma cell growth by DNA damage through increasing ROS levels. J Cell Mol Med 2022. [PMID: 35332658 DOI: 10.1111/jcmm.17260] [Reference Citation Analysis]
34 Bollati V, Ferrari L, Leso V, Iavicoli I. Personalised Medicine: implication and perspectives in the field of occupational health. Med Lav 2020;111:425-44. [PMID: 33311418 DOI: 10.23749/mdl.v111i6.10947] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Mangin MA, Boespflug A, Maucort Boulch D, Vacheron CH, Carpentier I, Thomas L, Dalle S. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Med 2021;10:3155-64. [PMID: 33932099 DOI: 10.1002/cam4.3760] [Reference Citation Analysis]
36 Carrié L, Virazels M, Dufau C, Montfort A, Levade T, Ségui B, Andrieu-Abadie N. New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells 2020;9:E1967. [PMID: 32858889 DOI: 10.3390/cells9091967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
37 Park H, Baek K. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188736] [Reference Citation Analysis]
38 Cui H, Wang Q, Miller DD, Li W. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. Front Pharmacol 2021;12:637098. [PMID: 33841154 DOI: 10.3389/fphar.2021.637098] [Reference Citation Analysis]
39 Singhal SS, Srivastava S, Mirzapoiazova T, Horne D, Awasthi S, Salgia R. Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Lett 2021;518:10-22. [PMID: 34126193 DOI: 10.1016/j.canlet.2021.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Wen L, Hyoju R, Wang P, Shi L, Li C, Li M, Wang X. Hydrogen-Peroxide-Responsive Protein Biomimetic Nanoparticles for Photothermal-Photodynamic Combination Therapy of Melanoma. Lasers Surg Med 2021;53:390-9. [PMID: 32596824 DOI: 10.1002/lsm.23292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chatterjee S, Chakraborty R, Hasija Y. Polymorphisms at site 469 of B-RAF protein associated with skin melanoma may be correlated with dabrafenib resistance: An in silico study. J Biomol Struct Dyn 2021;:1-16. [PMID: 34278963 DOI: 10.1080/07391102.2021.1950571] [Reference Citation Analysis]
42 Li H, Wang Y, Su R, Jia Y, Lai X, Su H, Fan Y, Wang Y, Xing W, Qin J. Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells. Front Oncol 2022;12:794216. [DOI: 10.3389/fonc.2022.794216] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kang JY, Kim KE. Prognostic Value of Interleukin-32 Expression and Its Correlation with the Infiltration of Natural Killer Cells in Cutaneous Melanoma. J Clin Med 2021;10:4691. [PMID: 34682815 DOI: 10.3390/jcm10204691] [Reference Citation Analysis]
44 Chiu YJ, Yang JS, Tsai FJ, Chiu HY, Juan YN, Lo YH, Chiang JH. Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway. Environ Toxicol 2022. [PMID: 34994998 DOI: 10.1002/tox.23450] [Reference Citation Analysis]
45 Sun CY, Li YZ, Cao D, Zhou YF, Zhang MY, Wang HY. Rapamycin and trametinib: a rational combination for treatment of NSCLC. Int J Biol Sci 2021;17:3211-23. [PMID: 34421360 DOI: 10.7150/ijbs.62752] [Reference Citation Analysis]
46 Li Q, Hou J, Guo C, Zhang Y, Liu L, Hu H, Shi S, Ji Y, Guo L, Shi Y, Liu Y, Cui H. ZC3H15 Correlates with a Poor Prognosis and Tumor Progression in Melanoma. Biomed Res Int 2021;2021:8305299. [PMID: 34988227 DOI: 10.1155/2021/8305299] [Reference Citation Analysis]
47 Rashid S, Tsao H. Recognition, Staging, and Management of Melanoma. Med Clin North Am 2021;105:643-61. [PMID: 34059243 DOI: 10.1016/j.mcna.2021.04.005] [Reference Citation Analysis]
48 Pinto CA, Liu X, Li X, Scherrer E, Kalabis M. Treatment and overall survival among anti-PD-1-exposed advanced melanoma patients with evidence of disease progression. Immunotherapy 2021. [PMID: 34870445 DOI: 10.2217/imt-2021-0214] [Reference Citation Analysis]
49 Vachtenheim J, Ondrušová L. Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas. Life (Basel) 2021;11:424. [PMID: 34063141 DOI: 10.3390/life11050424] [Reference Citation Analysis]
50 Mieczkowska K, Jacob J, Paoluzzi L, Papalezova KT, Mclellan BN, Amin B. Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors. Melanoma Research 2022;32:128-9. [DOI: 10.1097/cmr.0000000000000784] [Reference Citation Analysis]
51 Ren M, Wang L, Gao Z, Deng X, Shen K, Li Y, Ding Y, Wei C, Gu J. Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid. Bioengineered 2022;13:13571-86. [DOI: 10.1080/21655979.2022.2080385] [Reference Citation Analysis]
52 Thompson EL, Hu JJ, Niedernhofer LJ. The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma. Cancers (Basel) 2021;13:2241. [PMID: 34066966 DOI: 10.3390/cancers13092241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Bruneel K, Verstappe J, Vandamme N, Berx G. Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression. Cancers (Basel) 2020;12:E2248. [PMID: 32796736 DOI: 10.3390/cancers12082248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
54 Pinto M, Marotta N, Caracò C, Simeone E, Ammendolia A, de Sire A. Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach. Front Oncol 2022;12:843611. [PMID: 35402230 DOI: 10.3389/fonc.2022.843611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]